Note 10 - BioLargo Energy Technologies, Inc.	9 Months Ended
Sep. 30, 2025
BioLargo Energy Technologies, Inc (BETI) [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	*Note 10.* BioLargo Energy Technologies, Inc.** BioLargo Energy Technologies, Inc. (“BETI”) was formed for the purpose of commercializing a proprietary liquid sodium battery technology. BioLargo purchased 9,000,000 shares of its common stock upon its formation and was initially its sole stockholder. During the three months ended September 30, 2025, BETI sold 27,017 shares of its common stock at $3.70 per share to on accredited investor and received $100,000 in gross and net proceeds. During the three months ended March 31, 2024, BETI sold 20,000 shares of its common stock at $2.50 per share to one accredited investor and received $50,000 in gross and net proceeds. The investors entered into an agreement with BioLargo whereby the investor may exchange some or all of its shares of BETI common stock into shares of BioLargo common stock, at a price equal to a 20% discount of the volume weighted average price over the 20 trading days prior to the election to exchange. Elections must be made prior to December 31, 2025. During the three months ended September 30, 2025, an investor elected to exchange 25,000 shares of BETI common stock into 153,261 shares of BioLargo common stock. In exchange for the issuance of the shares of BioLargo common stock, BioLargo received and now holds the 25,000 exchanged shares of BETI common stock. As of September 30, 2025, BETI had 9,514,027 issued and outstanding shares, of which BioLargo holds 9,095,000 (96%).

Note 10 - BioLargo Energy Technologies, Inc.

9 Months Ended

Sep. 30, 2025

BioLargo Energy Technologies, Inc (BETI) [Member]

Noncontrolling Interest Disclosure [Text Block]

Note 10. BioLargo Energy Technologies, Inc.

BioLargo Energy Technologies, Inc. (“BETI”) was formed for the purpose of commercializing a proprietary liquid sodium battery technology. BioLargo purchased 9,000,000 shares of its common stock upon its formation and was initially its sole stockholder.

During the three months ended September 30, 2025, BETI sold 27,017 shares of its common stock at $3.70 per share to on accredited investor and received $100,000 in gross and net proceeds. During the three months ended March 31, 2024, BETI sold 20,000 shares of its common stock at $2.50 per share to one accredited investor and received $50,000 in gross and net proceeds. The investors entered into an agreement with BioLargo whereby the investor may exchange some or all of its shares of BETI common stock into shares of BioLargo common stock, at a price equal to a 20% discount of the volume weighted average price over the 20 trading days prior to the election to exchange. Elections must be made prior to December 31, 2025.

During the three months ended September 30, 2025, an investor elected to exchange 25,000 shares of BETI common stock into 153,261 shares of BioLargo common stock. In exchange for the issuance of the shares of BioLargo common stock, BioLargo received and now holds the 25,000 exchanged shares of BETI common stock.

As of September 30, 2025, BETI had 9,514,027 issued and outstanding shares, of which BioLargo holds 9,095,000 (96%).